COVID-19 is also manifested with hypercoagulability, pulmonary intravascular coagulation,
microangiopathy, and venous thromboembolism (VTE) or arterial thrombosis. Predisposing …

Abstract Coronavirus disease-2019 (COVID-19), a viral respiratory illness caused by the
severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), may predispose patients …

Background Antithrombotic guidance statements for hospitalized patients with coronavirus
disease 2019 (COVID‐19) suggest a universal thromboprophylactic strategy with potential to …

Coronavirus disease 2019 (COVID-19) has caused a global pandemic in just a few months,
causing millions infected. Nearly 20% of COVID-19 patients present severe coagulation …

This study aims to review the available literature pertinent to vascular complications in
COVID-19. A systematic search was performed using PubMed and Google Scholar to …

Antithrombotic agents reduce risk of thromboembolism in severely ill patients. Patients with
coronavirus disease 2019 (COVID‐19) may realize additional benefits from heparins …

Background: COVID-19 (coronavirus disease 2019) is associated with heightened risks of
venous and arterial thrombosis and hospitalization due to respiratory failure. To assess …

Abstract Background The Lombardy region suffered severely during the acute phase of the
coronavirus disease 2019 outbreak in Italy (Mar–Apr 2020) with 16,000 diagnosed …

Coronavirus-2019 (COVID-19) predisposes patients to arterial and venous thrombosis
commonly complicating the clinical course of hospitalized patients and attributed to the …

Background COVID-19 is associated with both venous and arterial thrombotic complications.
While prophylactic anticoagulation is now widely recommended for hospitalized patients …